Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spero Therapeutics LLC

Enfeebling Pseudomonas with a chemical inhibitor of transcription

This article was originally published in Start Up

Executive Summary

Spero Therapeutics LLC was formed to develop antibiotics based on a novel mechanism, to treat infections with high unmet need. Its lead program, initiated in 2013, commercializes the research of Laurence Rahme of Mass General, who invented a method for using small molecules to inhibit MvfR, a transcription regulator utilized by gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella.

You may also be interested in...

Antibiotic Incentives Helped Spero Get Where It Is Today

The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.

Infectious Disease, Options Prevalent In 2014 Start-Up Dealmaking

The number of deals signed by biopharma start-ups increased 7% in 2014, which featured a bump in partnerships for infectious disease drugs and multiple option-to-acquire agreements.

Spero Teams With Roche To Target Gram-Negative Pathogens

Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts